Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients (CADIRIS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2012 by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
University of Witwatersrand, South Africa
Case Western Reserve University
The Wistar Institute
University of Pennsylvania
Information provided by (Responsible Party):
Juan G. Sierra Madero, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
ClinicalTrials.gov Identifier:
NCT00988780
First received: October 1, 2009
Last updated: November 22, 2012
Last verified: November 2012

October 1, 2009
November 22, 2012
December 2009
March 2013   (final data collection date for primary outcome measure)
Time to occurrence of an IRIS event [ Time Frame: The initial 24 week period of observation ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00988780 on ClinicalTrials.gov Archive Site
  • Time to occurrence of a severe IRIS event [ Time Frame: The initial 24 week period of observation ] [ Designated as safety issue: No ]
  • Occurrence of either an IRIS event or death [ Time Frame: By 24 and 48 weeks ] [ Designated as safety issue: Yes ]
  • Proportion of subjects who develops an IRIS case [ Time Frame: By week 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects who develop a severe IRIS case [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects who develop a confirmed, non dermatologic IRIS case [ Time Frame: Week 24 ] [ Designated as safety issue: No ]
  • Proportion of subjects who develop an unmasking or paradoxical IRIS event [ Time Frame: Week 24 ] [ Designated as safety issue: Yes ]
  • Frequency of cardiovascular, cerebrovascular, non AIDS related neoplasia, cirrhosis, renal failure and death in both treatment arms [ Time Frame: During the study (from entry to week 60) ] [ Designated as safety issue: Yes ]
  • Frequency of AIDS defining events and AIDS related events in both arms of treatment [ Time Frame: From basline to study end ] [ Designated as safety issue: No ]
  • General survival [ Time Frame: At week 24 and 48 ] [ Designated as safety issue: No ]
  • Survival without IRIS [ Time Frame: At weeks 24 and 48 ] [ Designated as safety issue: No ]
  • Proportion of patients with VL<50 copies/mL [ Time Frame: At weeks 8, 24 and 48 ] [ Designated as safety issue: No ]
  • Changes form baseline in CD4+ cells count [ Time Frame: From baseline to weeks 12, 24 and 48 ] [ Designated as safety issue: No ]
  • Safety and tolerability of the treatment regimens [ Time Frame: Along the study ] [ Designated as safety issue: Yes ]
  • Incidence of HIV drug resistance [ Time Frame: Baseline to week 60 ] [ Designated as safety issue: No ]
  • Prevalence of CCR5 tropism [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Prevalence of CCR5 HIV tropism [ Time Frame: At virological failure occurrence ] [ Designated as safety issue: No ]
  • Baseline predictors of IRIS [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Genetic polymorphisms associated with the occurrence of IRIS [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • To evaluate the rol of biomarkers (CRP) in predicting or identifying IRIS and the effect of Maraviroc on this marker [ Time Frame: Baseline to IRIS event ] [ Designated as safety issue: No ]
  • Time to occurrence of a severe IRIS event [ Time Frame: The initial 24 week period of observation ] [ Designated as safety issue: No ]
  • Occurrence of either an IRIS event or death [ Time Frame: The initial 24 week period of observation ] [ Designated as safety issue: Yes ]
  • Occurrence of either an IRIS event or death [ Time Frame: First 48 weeks of study ] [ Designated as safety issue: Yes ]
  • Occurrence of virological failure [ Time Frame: At week 8 ] [ Designated as safety issue: No ]
  • Occurrence of virological failure [ Time Frame: At week 24 ] [ Designated as safety issue: No ]
  • Occurrence of virological failure [ Time Frame: At week 48 ] [ Designated as safety issue: No ]
  • Number of CD4+ lymphocytes [ Time Frame: At week 12 ] [ Designated as safety issue: No ]
  • Number of CD4+ lymphocytes [ Time Frame: At week 24 ] [ Designated as safety issue: No ]
  • Number of CD4+ lymphocytes [ Time Frame: At week 48 ] [ Designated as safety issue: No ]
  • Change in CD4+ counts [ Time Frame: From baseline to week 12 ] [ Designated as safety issue: No ]
  • Change in CD4+ counts [ Time Frame: From week 12 to week 48 ] [ Designated as safety issue: No ]
  • Occurrence of cardiovascular, cerebrovascular, non AIDS related neoplasia, cirrhosis and renal failure [ Time Frame: During the study (from entry to week 60) ] [ Designated as safety issue: Yes ]
  • Occurrence of any Maraviroc-related toxicity that warrants discontinuation of Maraviroc [ Time Frame: During the study (from entry to week 48) ] [ Designated as safety issue: Yes ]
  • Occurrence of any severe IRIS event [ Time Frame: During the study (from entry to week 48) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients
CCR5 Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

The purpose of this study is to determine if Maraviroc administration can decrease IRIS incidence in HIV infected patients initiating ARV therapy.

This is a randomized, double blind, placebo-controlled, multicenter study testing the utility of a CCR5 antagonist (Maraviroc) as an adjuvant to a standard HAART regimen to decrease the incidence of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-infected patients naïve to antiretroviral treatment. The study duration will be 60 weeks, 276 subjects (138 per arm) will be recruited. The population included will be HIV-infected patients starting antiretroviral (ARV) therapy at the participating centers in Mexico and South Africa with a CD4 T cell count <100 cells/ul. Subjects will be randomized to receive either Maraviroc (study drug) or placebo in addition to background ARV therapy. The background antiretroviral regimen for all subjects will be: Efavirenz 600mg QD + Tenofovir 300 mg / Emtricitabine 200 mg QD; subjects will be randomized to one of the following arms: Arm A: background ARV + maraviroc 600mg po BID; Arm B: background ARV + placebo po BID. Patients will be followed for 48 weeks. The primary endpoint will be the occurrence of a defined IRIS event by week 24 of follow up. The success of the ARV therapy will also be evaluated by virologic and immunologic response at 24 and 48 weeks. Three immunology sub-studies are planned: 1) Sub-study A will be conformed by a subgroup of 40 subjects (20 from Mexico and 20 from South Africa), additional blood sampling will be performed to evaluate expression of immune activation markers; movement of central memory T cells into cell cycle and frequencies of expandable pathogen-reactive CD4+ and CD8+ T cells in circulation; 2) Sub-study B will be conformed by another subgroup of 60 subjects (all from South Africa), additional blood sampling will be performed to evaluate monocyte and CD4 T cell gene expression as related to activation-induced apoptosis and cytokine secretion.; 3) Sub-study C will evaluate the incidence of thromboembolic disease in the study patients along with baseline evaluation of possible bio-markers of pro-coagulant state.

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
  • Immune Reconstitution Inflammatory Syndrome
  • HIV
  • HIV Infections
  • Drug: maraviroc

    Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.

    Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.

    Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.

    Other Names:
    • Selzentry
    • Stocrin
    • Truvada
  • Drug: Placebo

    Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.

    Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.

    Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.

    Other Names:
    • Stocrin
    • Truvada
  • Experimental: Maraviroc

    Maraviroc 600mg po BID

    Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD) plus Maraviroc 600 mg BID

    Intervention: Drug: maraviroc
  • Placebo Comparator: Placebo

    Placebo po BID

    Background antiretroviral regimen (Efavirenz 600mg QD + Tenofovir 300 mg /Emtricitabine 200 mg QD plus Placebo po BID

    Intervention: Drug: Placebo

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
276
April 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-1 infection, as documented by any licensed rapid test kit and confirmed by Western blot or ELISA test kit at any time prior to study enrollment.

Plasma HIV-1 RNA is acceptable as an alternative confirmatory test.

  • Men and women age > 18 years.
  • Have not received any antiretroviral treatment before entering the study.
  • Patients who received Single dose nevirapine or any duration of AZT for PMTC will not be considered ARV naïve.
  • CD4+ cell count of </=100 cells/mm3 obtained within 90 days prior to study entry.
  • HIV RNA level > 1,000 copies/mL obtained within 90 days prior to study entry.
  • Patients with an opportunistic or HIV-related infection may be included according to the clinical judgment of the main investigator in each center when the patient is ready and able to start ARV therapy.
  • Laboratory values obtained within 30 days prior to study entry:

    • Absolute neutrophil count (ANC) > 500/mm3.
    • Hemoglobin > 8.0 g/dL.
    • Platelet count > 50,000/mm3.
    • AST (SGOT), ALT (SGPT), and alkaline phosphatase minor of 5 times ULN.
    • Total bilirubin minor of 2.5 times ULN.
    • Creatinine clearance minor of 50* mL/min as estimated by the Cockcroft-Gault equation or Creatinine Clearance > 50ml/min as calculated by a formal creatinine clearance measurement
  • All women of reproductive potential (have not reached menopause or undergone hysterectomy, oophorectomy, or tubal ligation) must have a negative serum or urine b-HCG pregnancy test performed within 7 days before study entry.
  • Female subjects who are not of reproductive potential (have reached menopause or undergone hysterectomy, oophorectomy, or tubal ligation) or whose male partner has undergone successful vasectomy with resultant azoospermia or has azoospermia for any other reason, are eligible without requiring the use of contraception. Documentation of menopause, sterilization (hysterectomy, oophorectomy, tubal ligation, or vasectomy) and azoospermia by patient-reported history is acceptable.
  • All subjects must agree not to participate in a conception process (i.e., active attempt to become pregnant or to impregnate, sperm donation, in vitro fertilization), and if participating in sexual activity that could lead to pregnancy, the female study volunteer/male partner must agree to use a form of contraception as specified in the note below while receiving protocol-specified medication(s) and for one month after stopping the medication(s).
  • Ability and willingness of subject or legal guardian/representative to give written informed consent.

Exclusion Criteria:

  • Pregnancy and breast-feeding.
  • Active neoplasia or previous history of neoplasia. (Except localized non visceral Kaposi´s Sarcoma; localized squamous or basal cell carcinoma of the skin, or intraepithelial cervical neoplasia grade III or less).
  • Use of the following drugs within 180 days prior to study entry: systemic cancer chemotherapy, systemic investigational agents, and immunomodulators (growth factors, immune globulin, interleukins, interferons).
  • Use of systemic corticosteroids in the last 2 weeks prior to randomization.
  • Decompensated liver disease (defined as stage C of Child-Pugh classification) at the beginning of the study.
  • An altered mental status that in the opinion of the investigator, will compromise the adherence to the protocol.
  • Allergy/sensitivity to study drug(s) or their formulations that cannot be substituted by another agent as described in section 5.1
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
  • Serious illness that renders a subject unable to take the antiretroviral study regimen.
  • Serious medical illness that in the opinion of the investigator compromises the adherence and/or follow up of the protocol.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Mexico,   South Africa
 
NCT00988780
The CADIRIS Study
Yes
Juan G. Sierra Madero, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
  • University of Witwatersrand, South Africa
  • Case Western Reserve University
  • The Wistar Institute
  • University of Pennsylvania
Principal Investigator: Ian Sanne, MBBCH, FCP University of the Witwatersrand. Themba Lethu Clinic.
Principal Investigator: Michael M. Lederman, MD Center for AIDS Research. Case Western Reserve University
Principal Investigator: Luis J Montaner, M.Sc. HIV-1 Immunopathogenesis Laboratory. The Wistar Institute
Principal Investigator: Livio Azzoni, MD, PhD HIV-1 Immunopathogenesis Laboratory. The Wistar Institute
Principal Investigator: Juan G Sierra Madero, MD Insituto Nacional de Nutricion de Ciencias Medicas y Nutricion Salvador Zubiran
Principal Investigator: Susan Ellenberg, Ph.D. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine
Principal Investigator: Irini Sereti, M.D., MHS NIH/NIAID
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP